CEBPZ and acute myeloid leukemia: The incidence of KIT mutation was approximately 4%−6% in AML [9, 10], which frequently occurred in 10%−40% CBF-AML, with a poor survival in the subgroup of patients with RUNX1::RUNXT1 based on multiple retrospective and perspective clinical studies [11, 15, 18–22].